Electrostatic co-assembly of FePS3 nanosheets and surface functionalized BCN heterostructures for hydrogen evolution reaction.

Advances in the hydrogen evolution reaction (HER) are intricately connected with addressing the current energy crisis and quest for sustainable energy sources. The necessity of catalysts that are efficient and inexpensive to perform the hydrogen evolution reaction is key to this. Following the ground-breaking discovery of graphene, metal thio/seleno phosphates (MPX3: M - transition metal, P - phosphorus and X - S/Se), two dimensional (2D) materials, exhibit excellent tunable physicochemical, electronic and optical properties, and are expected to be key to the energy industry for years to come. Taking this into account, a facile time-effective electrostatic restacking synthesis procedure has been followed to synthesize a 2D/2D heterostructure (FePS3@BCN) involving FePS3, one of the prominent MPX3 materials, with borocarbonitride (BCN), for hydrogen evolution reaction (HER). The piled up nanosheets of FePS3 and BCN are held together by an electrostatic force, and display extreme robustness under the harsh conditions of HER application. The amalgamated electrocatalyst achieved an overpotential of 187 mV at a current density of 10 mA cm-2 with a shallow Tafel slope of 41 mV dec-1, following the Volmer-Heyrovsky mechanism. The resilience of the electrocatalyst has been examined through chronoamperometric testing for long term stability, and it is stable for more than 14 hours, which shows the excellent electrocatalytic activity for hydrogen evolution reaction owing to the strategic approach to the catalyst design, the use of numerous electrochemically active sites, large surface area and a barrier-free channel for quick ion transfer.

Network interactions with functional roles and evolutionary relationships for BURP domain-containing proteins in chickpea and model species.

The functional significance and evolutionary relationships of BURP domain-containing genes unique to plants is of interest. Network analysis reveals different associations of BURP proteins with other proteins and functional terms, throwing light on their involvement in various biological processes and pathways. The gene expression data reveals that BURP genes are affected by salinity stress, reflecting diverse expression patterns in roots and shoots.

Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical study.

PURPOSE: The efficacy and safety of ßeta-3 agonists (Mirabegron 50 mg) have been sparingly assessed in the published English literature. We aim to do an efficacy-safety analysis of Mirabegron-Tamsulosin combination therapy vs tamsulosin-placebo monotherapy in a select subset of medication virgin Benign Prostatic Enlargement (BPE) patients with coexisting predominant non-neurogenic overactive bladder symptoms (OABS). METHODS: After prior written informed consent and IEC, 80 patients of uncomplicated BPE with coexisting non-neurogenic OABS and IPSS of >7 without contraindications to drug therapy were computer randomised/allocated to receive either[50 mg Mirabegron plus Tamsulosin 0.4 mg (Intervention arm-I)]or [Tamsulosin 0.4 mg plus capsule lactobacillus (Comparator arm-II)] once daily for 8 weeks. Efficacy was evaluated using the OABS Score (OABSS), mean change in nocturnal frequency (NF), PVR and IPSS, while safety was assessed by recording treatment emergent adverse events (TEAE). Follow-up visits were performed at second, fourth and eighth week. RESULTS: Patient data in both groups were generally comparable with the exception of NF and IPSS storage sub score (IPSS-ss). Significant improvements were visualised in the eighth week primary endpoint total OABS sub score (OABSS-ss) in the combination group (P < .001).Similar significant improvements were seen with most secondary parameters such as the mean change in NF, IPSS, IPSS-ss, OABS-ss, voided volume, Qmax, and Quality of life index (QOL) (P < .001). No significant increase in PVR was observed in the Mirabegron arm and no patient developed urinary retention. The TEAE were minor, self-limiting and managed symptomatically without drug discontinuity. CONCLUSION: Mirabegron can be significantly efficacious and safe in ameliorating non-neurogenic OABS induced by BPE vs placebo by initiating combination therapy from the start as opposed to the usual 'add on therapy' protocol. This combination appeared to be superior in terms of overall safety, minimal side effects, better compliance and tolerability vs Tamsulosin monotherapy in select BPE patients with predominant non-neurogenic OABS.

Two cases of hereditary fructose intolerance.

Hereditary fructose intolerance is a rare cause of hepatic cirrhosis in the young. The disorder has a reported frequency of 1 in 20000 live births and no case has been reported from India so far. We report two cases of hereditary fructose intolerance, both with bilateral cataracts and one with cirrhosis of the liver.